Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in ...

Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing ...

Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) American Cough Conference June 6 – 7, 2025, Dulles, Virginia Oral Presentation: June 6, 4:05 p.m. ET ...

The cough reflex can also be triggered by a range of chemicals, like those contained in cigarette or wildfire smoke, as well as toxic gases and stomach juice that can sometimes backtrack into the ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline ...

When a mouthful of water goes down the wrong pipe – heading toward a healthy person’s lungs instead of their gut – they start coughing uncontrollably. That’s because their upper airway senses the ...

The same coughing reflex is set off in people with acid reflux, when acid from the stomach reaches the throat. Now, UC San Francisco scientists have identified the rare type of cell responsible ...

Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough.